Literature DB >> 14532160

Rheumatoid arthritis in 2003: where are we now with treatment?

M E Weinblatt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14532160      PMCID： PMC1766746          DOI： 10.1136/ard.62.suppl_2.ii94

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  21 in total

1.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Authors:  T Möttönen; P Hannonen; M Leirisalo-Repo; M Nissilä; H Kautiainen; M Korpela; L Laasonen; H Julkunen; R Luukkainen; K Vuori; L Paimela; H Blåfield; M Hakala; K Ilva; U Yli-Kerttula; K Puolakka; P Järvinen; M Hakola; H Piirainen; J Ahonen; I Pälvimäki; S Forsberg; K Koota; C Friman
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

2.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

Authors:  J M Bathon; R W Martin; R M Fleischmann; J R Tesser; M H Schiff; E C Keystone; M C Genovese; M C Wasko; L W Moreland; A L Weaver; J Markenson; B K Finck
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.

Authors:  Tuulikki Sokka; Theodore Pincus
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

4.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

Authors:  Hyon K Choi; Miguel A Hernán; John D Seeger; James M Robins; Frederick Wolfe
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

5.  Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

Authors:  Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; Jorma Ilonen; Leena Laasonen; Oili Kaipiainen-Seppänen; Per Franzen; Tapani Helve; Juhani Koski; Marianne Gripenberg-Gahmberg; Riitta Myllykangas-Luosujärvi; Marjatta Leirisalo-Repo
Journal:  Arthritis Rheum       Date:  2002-04

6.  Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone.

Authors:  S M Proudman; P G Conaghan; C Richardson; B Griffiths; M J Green; D McGonagle; R J Wakefield; R J Reece; S Miles; A Adebajo; A Gough; P Helliwell; M Martin; G Huston; C Pease; D J Veale; J Isaacs; D M van der Heijde; P Emery
Journal:  Arthritis Rheum       Date:  2000-08

7.  Mortality in rheumatoid arthritis: have we made an impact in 4 decades?

Authors:  S E Gabriel; C S Crowson; W M O'Fallon
Journal:  J Rheumatol       Date:  1999-12       Impact factor: 4.666

8.  Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95.

Authors:  Lena Björnådal; Eva Baecklund; Li Yin; Fredrik Granath; Lars Klareskog; Anders Ekbom
Journal:  J Rheumatol       Date:  2002-05       Impact factor: 4.666

9.  A 10 year prospective followup of patients with rheumatoid arthritis 1986-96.

Authors:  P Gordon; J West; H Jones; T Gibson
Journal:  J Rheumatol       Date:  2001-11       Impact factor: 4.666

Review 10.  The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials.

Authors:  G Jones; J Halbert; M Crotty; E M Shanahan; M Batterham; M Ahern
Journal:  Rheumatology (Oxford)       Date:  2003-01       Impact factor: 7.580
View more
  10 in total

1.  Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.

Authors:  M E Weinblatt; E C Keystone; D E Furst; A F Kavanaugh; E K Chartash; O G Segurado
Journal:  Ann Rheum Dis       Date:  2005-11-24       Impact factor: 19.103

2.  Sensory and vascular changes in a rat monoarthritis model: prophylactic and therapeutic effects of meloxicam.

Authors:  Javeria Ali Hashmi; Kiran Yashpal; David W Holdsworth; James L Henry
Journal:  Inflamm Res       Date:  2010-03-28       Impact factor: 4.575

3.  Serum levels of calreticulin in correlation with disease activity in patients with rheumatoid arthritis.

Authors:  Min Ni; Wei Wei; Yichao Wang; Na Zhang; Hongmei Ding; Chen Shen; Fang Zheng
Journal:  J Clin Immunol       Date:  2013-03-27       Impact factor: 8.317

Review 4.  Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy.

Authors:  Juan Ignacio Villa-Blanco; Jaime Calvo-Alén
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  Utilization of adjuvant arthritis model for evaluation of new approaches in rheumatoid arthritis therapy focused on regulation of immune processes and oxidative stress.

Authors:  Katarína Bauerová; Silvester Poništ; Danica Mihalová; František Dráfi; Viera Kuncírová
Journal:  Interdiscip Toxicol       Date:  2011-03

6.  Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure.

Authors:  Theresa Kapral; Tanja Stamm; Klaus P Machold; Karin Montag; Josef S Smolen; Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2006-02-24       Impact factor: 5.156

7.  Effect of N-Feruloylserotonin and Methotrexate on Severity of Experimental Arthritis and on Messenger RNA Expression of Key Proinflammatory Markers in Liver.

Authors:  Ľudmila Pašková; Viera Kuncírová; Silvester Poništ; Danica Mihálová; Radomír Nosáľ; Juraj Harmatha; Iveta Hrádková; Tomáš Čavojský; František Bilka; Katarína Šišková; Ingrid Paulíková; Lýdia Bezáková; Katarína Bauerová
Journal:  J Immunol Res       Date:  2016-07-31       Impact factor: 4.818

8.  Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study.

Authors:  Marieke Voshaar; Johanna Vriezekolk; Sandra van Dulmen; Bart van den Bemt; Mart van de Laar
Journal:  BMC Musculoskelet Disord       Date:  2016-10-21       Impact factor: 2.362

9.  Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration.

Authors:  Kristin Andreas; Thomas Häupl; Carsten Lübke; Jochen Ringe; Lars Morawietz; Anja Wachtel; Michael Sittinger; Christian Kaps
Journal:  Arthritis Res Ther       Date:  2009-02-03       Impact factor: 5.156

Review 10.  Developments in the clinical understanding of rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.